A tight junction-associated Merlin-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functions
about
Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleusNeurofibromatosis type 2 protein, NF2: an uncoventional cell cycle regulator.Rho GAPs and GEFs: controling switches in endothelial cell adhesionThe two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatmentMerlin Isoforms 1 and 2 Both Act as Tumour Suppressors and Are Required for Optimal Sperm MaturationStructural Basis of the Binding of Merlin FERM Domain to the E3 Ubiquitin Ligase Substrate Adaptor DCAF1Structural basis of DDB1-and-Cullin 4-associated Factor 1 (DCAF1) recognition by merlin/NF2 and its implication in tumorigenesis by CD44-mediated inhibition of merlin suppression of DCAF1 functionTargeting the Hippo Signaling Pathway for Tissue Regeneration and Cancer TherapyMolecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering studyEpithelial junctions and Rho family GTPases: the zonular signalosome.Regulation of localization and function of the transcriptional co-activator YAP by angiomotin.Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies.Development of drug treatments for neurofibromatosis type 2-associated vestibular schwannoma.Merlin/ERM proteins establish cortical asymmetry and centrosome position.Microarray analysis of gene expression in vestibular schwannomas reveals SPP1/MET signaling pathway and androgen receptor deregulation.Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.Genome-wide gene expression array identifies novel genes related to disease severity and excessive daytime sleepiness in patients with obstructive sleep apnea.Establishment of epithelial polarity--GEF who's minding the GAP?Angiomotin family proteins are novel activators of the LATS2 kinase tumor suppressor.Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinomaThe p130 isoform of angiomotin is required for Yap-mediated hepatic epithelial cell proliferation and tumorigenesis.Soluble melanoma cell adhesion molecule (sMCAM/sCD146) promotes angiogenic effects on endothelial progenitor cells through angiomotin.Polarity-dependent distribution of angiomotin localizes Hippo signaling in preimplantation embryos.Phosphorylation of angiomotin by Lats1/2 kinases inhibits F-actin binding, cell migration, and angiogenesisThe role of angiomotin phosphorylation in the Hippo pathway during preimplantation mouse development.Energy stress regulates hippo-YAP signaling involving AMPK-mediated regulation of angiomotin-like 1 protein.Angiomotin binding-induced activation of Merlin/NF2 in the Hippo pathwayHippo signaling pathway in liver and pancreas: the potential drug target for tumor therapy.Angiomotin-like2 gene (amotl2) is required for migration and proliferation of endothelial cells during angiogenesis.Angiomotin is a novel component of cadherin-11/β-catenin/p120 complex and is critical for cadherin-11-mediated cell migration.Aerobic glycolysis tunes YAP/TAZ transcriptional activityEzrin: a regulator of actin microfilaments in cell junctions of the rat testis.Merlin: a tumour suppressor with functions at the cell cortex and in the nucleus.The Amotl2 gene inhibits Wnt/β-catenin signaling and regulates embryonic development in zebrafishGrowth control by committee: intercellular junctions, cell polarity, and the cytoskeleton regulate Hippo signaling.Role of Merlin/NF2 inactivation in tumor biology.NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition.Convergent signaling in the regulation of connective tissue growth factor in malignant mesothelioma: TGFβ signaling and defects in the Hippo signaling cascade.Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration.Role of Angiomotin-like 2 mono-ubiquitination on YAP inhibition.
P2860
Q24300770-7534F086-09BE-46F6-AB9D-1ABFCA8209A2Q26825296-4740B5E3-4320-4ADB-891F-E30C49126834Q26992281-C2FAC8AC-A073-4974-A310-BA99C1A2ED95Q27025661-56726852-2065-4028-AC6F-FE22FDF5F862Q27304868-25B934C5-BFC9-4384-9A88-B6ABF3F3E89AQ27683013-1330A320-7A63-4C70-BF28-65958C0C481FQ27690668-16D2F9D4-C242-4673-95F6-D22C5152F418Q28078129-0C975064-D9F1-4C64-88CF-D5C16913EC63Q28241032-5EAF0B9B-0705-4090-9403-1C3976D01044Q30009261-12021691-3457-40B2-929D-1363EA24ED68Q30352874-E223FF7C-DAE0-4F4D-B6F2-143735D83B33Q30364937-A2B9D347-C896-46C2-B00B-B53AA7FF7DAEQ30389069-6D0E3AD8-5CE6-49DC-A3BE-AE741A674796Q30418770-B8BCAB0B-54AE-498A-9AE0-D8B7466A6F4BQ30456266-C458C3D7-C25C-43F1-AE84-23674256FB22Q33591646-4364139A-D334-4879-8876-CC07268C2B14Q33698969-1D2E951A-3123-4302-A41F-861E14E6F8B7Q33980507-2EFA6F67-12B8-4384-A907-A5C26F9727DBQ34207272-B45D161C-DB7D-490B-B135-2D3830804D3AQ34246014-4EA276A8-BF6C-4206-B455-D9A69F417024Q34246027-151DD48F-AB82-43EB-BB14-0C50AA82726FQ34326616-3BC8EFAB-083C-4D2B-B2B9-DCCBA471D095Q34352631-F0648454-9986-443A-AE69-1C903FD7F8E1Q34376255-068FDC9D-74F8-49C4-897F-9835E6639AE7Q34420716-FB79ADAC-E3C6-4B1A-B451-FD4C6085AC3BQ34469155-3D1DD7F7-4AC0-4723-88D3-0D965DE832A6Q34479368-6F943456-0CED-46DD-8A8E-6202BD16FC72Q35484837-B1D2785C-02EF-454B-8C29-BCB41809155FQ35562536-2152FF35-426F-478F-B526-D7140ED9F027Q35576534-0F31F0EF-85FF-4B2A-AF8D-DF6E541DBEFFQ35819661-C015C51E-FB8D-49E7-8C76-694B8DE67905Q35819867-5910B249-FF6F-424F-BEC8-A2157F9328AEQ35880377-BB113130-A020-4F97-A15E-3FA90041871BQ35921664-FFF86B15-A865-403F-9463-5480BBE30A8DQ36036191-8F055269-A71A-40E8-A14D-8AA2A13E4C65Q36189820-D889925E-0DB1-4031-924D-9152F18A64C5Q36273267-4B7C0FE7-7933-489C-8AF1-5BBDF1818E41Q36304149-7BA5D6E6-D832-4626-83FB-FA9287BE3A02Q36304907-F08B8366-0150-4C52-B7EE-ADB26437E80DQ36478653-563CC912-95EC-46DB-A267-A98CE8F6BCDE
P2860
A tight junction-associated Merlin-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functions
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A tight junction-associated Me ...... nd tumor suppressive functions
@ast
A tight junction-associated Me ...... nd tumor suppressive functions
@en
A tight junction-associated Me ...... nd tumor suppressive functions
@en-gb
A tight junction-associated Me ...... nd tumor suppressive functions
@nl
type
label
A tight junction-associated Me ...... nd tumor suppressive functions
@ast
A tight junction-associated Me ...... nd tumor suppressive functions
@en
A tight junction-associated Me ...... nd tumor suppressive functions
@en-gb
A tight junction-associated Me ...... nd tumor suppressive functions
@nl
prefLabel
A tight junction-associated Me ...... nd tumor suppressive functions
@ast
A tight junction-associated Me ...... nd tumor suppressive functions
@en
A tight junction-associated Me ...... nd tumor suppressive functions
@en-gb
A tight junction-associated Me ...... nd tumor suppressive functions
@nl
P2093
P2860
P3181
P1433
P1476
A tight junction-associated Me ...... nd tumor suppressive functions
@en
P2093
Akihiko Shimono
Anat Stemmer-Rachamimov
Chunling Yi
David W Speicher
Jacqueline L Avila
Joseph L Kissil
Lars Holmgren
Nathalie Luna Persson
Neepa Christian
Scott Troutman
P2860
P304
P3181
P356
10.1016/J.CCR.2011.02.017
P407
P577
2011-04-12T00:00:00Z